Kira Pharmaceuticals appoints Teri Loxam as COO and CFO


“We are delighted to welcome Teri to the Kira leadership team. As Kira continues to gain momentum and progress in the clinic, Teri’s wealth of experience in finance, strategy, investor relations and communications will be invaluable ”said Frederick Beddingfield, MD, PhD, CEO of Kira Pharmaceuticals. “We will benefit from his strong relationships with the life science and investment communities and his strength in operational execution and team building as we continue to grow and deliver much-needed therapies to patients. “

Ms. Loxam joins Kira from SQZ Biotechnologies, where she served as Chief Financial Officer and was instrumental in collecting more than $ 200 million, including the company’s IPO, to advance the company’s new cell therapy platforms. Previously, she was Senior Vice President of Investor Relations and Global Communications at Merck, Vice President of Investor Relations at IMAX, supporting the company’s IPO on the Hong Kong exchanged and held senior strategic positions at Bristol-Myers Squibb. Ms. Loxam also currently sits on the board of directors of Vaxcyte and as an advisor to Cardiol Therapeutics, two publicly traded companies. Ms. Loxam holds an MBA from the University of California Irvine Paul Merage School of Business and a Bachelor of Science in Biology from University of Victoria.

“I am honored to join Kira at this critical stage in the company’s growth. With its primary clinical asset, P014, in the multi-dose escalation portion of its Phase 1 trial and aiming to deliver it to patients next year, along with a differentiated pipeline of additional assets, Kira has the potential to transform the ‘complement space and to advance treatments important to help people living with complement-mediated diseases,’ said Ms. Loxam. “In addition, the company’s global mission and its US-China structure provide a unique opportunity to leverage talents and capabilities across the globe. programs to have an impact on patients.

About Kira Pharmaceuticals
Kira Pharmaceuticals is a global biotechnology company pioneering targeted complement therapies to treat immune mediated diseases. Through its LOGIC drug discovery platform, the company is committed to advancing world-class, best-in-class therapies to transform patients’ lives. With offices in Cambridge, Massachusetts, and facilities in Suzhou and Shanghai, China, Kira Pharmaceuticals is committed to establishing a global footprint and advancing life-changing therapies for patients around the world. You can find more information about Kira at as well as on LinkedIn.

SOURCE Kira Pharmaceuticals


Comments are closed.